Los puntos clave no están disponibles para este artículo en este momento.
Regulators and industry continue to prioritize survival-based end points rather than patient-experience end points in cancer-drug development. Yet as patients live longer with cancer, they must increasingly choose among agents with varying efficacy–toxicity balances.
Ethan Basch (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: